已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial

作者
Harold S. Nelson,James F. Donohue,Han Joo Kim,Bettina Hederer,Richard Beasley,Allen Moton,Michelle Clay,Rajendra H. Mehta
出处
期刊:
标识
DOI:10.17615/9j5r-0j36
摘要

ObjectiveTo investigate the safety and efficacy of QMF149, a once-daily, fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol maleate and inhaled corticosteroid (ICS) mometasone furoate (MF) for the treatment of persistent asthma. The hypothesis was that QMF149 would not increase the risk of serious asthma exacerbations.Setting174 research centres in nine countries.Participants1519 adolescents and adults with persistent asthma who were treated or qualified for treatment with combination LABA/ICS were randomised, and 1508 were included in the intention-to-treat analysis.InterventionPatients were randomised to QMF149 (indacaterol maleate 500 µg/MF 400 µg) or MF (400 µg) once daily via Twisthaler inhalation device in a double-blind, parallel-group study for 6–21 months.Primary and secondary outcome measuresThe primary end point was time to first serious asthma exacerbation (resulting in hospitalisation, intubation or death). The key secondary end point was annual rate of exacerbations requiring systemic corticosteroids.ResultsTreatment with QMF149 resulted in no significant difference in time to first serious exacerbation compared to MF (2 (0.3%) vs 6 events (0.8%); difference −0.52 percentage point; 95% CI −1.25 to 0.21, p=0.160, HR=0.31; 95% CI 0.06 to 1.54, p=0.151). QMF149 significantly reduced the annual rate of exacerbations requiring systemic corticosteroids (rate ratio=0.71; 95% CI 0.55 to 0.90, p=0.005). Proportions of patients experiencing adverse events were similar across groups (74.0% in the QMF149 group and 73.4% in the MF group). Serious adverse events occurred in 4% and 5.8% of patients in the QMF149 and MF groups, respectively.ConclusionsNo significant difference was observed in the primary outcome of time to first serious asthma exacerbation in patients treated with QMF149 compared with patients treated with MF. Long-term treatment with QMF149 once daily had a favourable safety/efficacy profile in adolescent and adult patients with persistent asthma.Trial registration numberClinicalTrials.gov; NCT00941798.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一点浩然气完成签到 ,获得积分10
1秒前
2秒前
研友_VZG7GZ的应助被zhang采纳,获得10
3秒前
4秒前
向未来完成签到,获得积分10
4秒前
威武的凡双完成签到,获得积分10
5秒前
所所的应助被无心的思松采纳,获得10
5秒前
6秒前
6秒前
FashionBoy的应助被liurong采纳,获得10
7秒前
7秒前
甜甜玉米完成签到 ,获得积分10
7秒前
8秒前
8秒前
Hello的应助被u511277采纳,获得10
9秒前
贾茜茜完成签到 ,获得积分10
9秒前
老莫发布了新的文献求助10
9秒前
巧巧发布了新的文献求助10
10秒前
11秒前
12秒前
lililili发布了新的文献求助10
12秒前
cc发布了新的文献求助10
14秒前
wan的应助被耍酷大山采纳,获得10
14秒前
gyq发布了新的文献求助10
14秒前
传奇3的应助被耍酷大山采纳,获得10
14秒前
科研通AI65的应助被耍酷大山采纳,获得10
14秒前
科研通AI6.4的应助被耍酷大山采纳,获得10
14秒前
sw123完成签到 ,获得积分10
14秒前
科研通AI6.2的应助被耍酷大山采纳,获得10
14秒前
科研通AI6.3的应助被耍酷大山采纳,获得10
15秒前
星辰大海的应助被耍酷大山采纳,获得10
15秒前
Maestro_S的应助被耍酷大山采纳,获得10
15秒前
Maestro_S的应助被耍酷大山采纳,获得10
15秒前
15秒前
16秒前
喜哦肖完成签到,获得积分10
17秒前
赵师傅发布了新的文献求助10
17秒前
完美世界的应助被M1采纳,获得10
17秒前
17秒前
等待的莹芝完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194612
求助须知:如何正确求助?哪些是违规求助? 9580394
关于积分的说明 21870930
捐赠科研通 7794182
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2561001
邀请新用户注册赠送积分活动 2484411